文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药对比伊匹木单抗治疗晚期黑色素瘤患者的长期结局

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
PubMed 文献 · J Clin Oncol · 2021-11-24

III期CheckMate 067试验报告6.5年疗效与安全性:晚期黑色素瘤患者随机接受纳武利尤单抗联合伊匹木单抗、纳武利尤单抗单药或伊匹木单抗。联合组中位总生存72.1个月,纳武利尤单抗组36.9个月,伊匹木单抗组19.9个月;联合组与纳武利尤单抗组较伊匹木单抗组显示持久改善的临床结局,描述性分析中联合组优于纳武利尤单抗单药。

要点

  • 联合组中位总生存72.1个月,纳武利尤单抗组36.9个月,伊匹木单抗组19.9个月。
  • 联合组中位黑色素瘤特异性生存未达到,纳武利尤单抗组58.7个月,伊匹木单抗组21.9个月。
  • 自5年分析以来未观察到新的安全性信号。

核心结论

  • 6.5年CheckMate 067结果包含迄今III期黑色素瘤试验中最长的中位总生存和首次黑色素瘤特异性生存报告,显示纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药对比伊匹木单抗在晚期黑色素瘤患者中带来持久、改善的临床结局,描述性分析中联合组优于纳武利尤单抗单药。

研究设计与样本

  • III期CheckMate 067试验,既往未治疗的不可切除III期或IV期黑色素瘤患者按1:1:1随机分配接受纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周一次(共四剂)后纳武利尤单抗3 mg/kg每2周一次(n=314)、纳武利尤单抗3 mg/kg每2周一次(n=316)或伊匹木单抗3 mg/kg每3周一次(共四剂;n=315)。
  • 共同主要终点为纳武利尤单抗联合伊匹木单抗或纳武利尤单抗对比伊匹木单抗的无进展生存和总生存;次要终点包括客观缓解率、纳武利尤单抗联合伊匹木单抗对比纳武利尤单抗单药的描述性疗效评估和安全性;另评估排除非黑色素瘤相关死亡的黑色素瘤特异性生存(描述性分析)。

主要发现

  • 中位总生存(最短随访6.5年)在联合组、纳武利尤单抗组和伊匹木单抗组分别为72.1、36.9和19.9个月。
  • 中位黑色素瘤特异性生存在联合组未达到,纳武利尤单抗组为58.7个月,伊匹木单抗组为21.9个月。
  • BRAF突变肿瘤患者的6.5年总生存率在联合组、纳武利尤单抗组和伊匹木单抗组分别为57%、43%和25%;BRAF野生型肿瘤患者分别为46%、42%和22%。
  • 在停止治疗的患者中,中位无治疗间隔在联合组、纳武利尤单抗组和伊匹木单抗组分别为27.6、2.3和1.9个月。
  • 自5年分析以来未观察到新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS: Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n = 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated. RESULTS: Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF-wild-type tumors, respectively. In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed. CONCLUSION: These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2021. PMID: 34818112. doi:10.1200/JCO.21.02229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。